Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 426.93% is 444% above its 5-year average of -124.17%, around the middle of its 5-year range (-447.94%–2164.20%).
59.37% above its 12-month average of 267.89%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -315.04%.
NET PROFIT MARGIN
426.93%
NET PROFIT MARGIN AVG TTM
267.89%
NET PROFIT MARGIN AVG 3Y
-162.51%
NET PROFIT MARGIN AVG 5Y
-124.17%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+59.37%
CURRENT VS 3Y AVG
+362.71%
CURRENT VS 5Y AVG
+443.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+164303.85%
vs the sector median at left
Elutia Inc
Market Cap
$34.35M
Net Profit Margin
426.93%
TTM Avg
267.89%
3Y Avg
-162.51%
5Y Avg
-124.17%
Market Cap
$34.97M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$33.63M
Net Profit Margin
-1414.57%
TTM Avg
-657.22%
3Y Avg
-405.12%
5Y Avg
-350.75%
Market Cap
$33.61M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-1673.30%
Market Cap
$33.29M
Net Profit Margin
-241.01%
TTM Avg
-2216.37%
3Y Avg
-1421.99%
5Y Avg
-1438.67%
Market Cap
$35.52M
Net Profit Margin
-65.31%
TTM Avg
-147.78%
3Y Avg
-3852.20%
5Y Avg
-3378.36%
Market Cap
$35.76M
Net Profit Margin
-65.29%
TTM Avg
-26.68%
3Y Avg
-11.11%
5Y Avg
-8.71%
Market Cap
$32.93M
Net Profit Margin
-121.04%
TTM Avg
-43.71%
3Y Avg
-4.52%
5Y Avg
10.54%
Market Cap
$35.84M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-322.60%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $34.35M | 426.93% | 267.89% | -162.51% | -124.17% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| Scilex Holding Company (SCLX)vs › | $33.63M | -1414.57% | -657.22% | -405.12% | -350.75% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | 0.00% | 0.00% | 0.00% | -1673.30% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | -241.01% | -2216.37% | -1421.99% | -1438.67% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | -65.31% | -147.78% | -3852.20% | -3378.36% |
| DocGo Inc. (DCGO)vs › | $35.76M | -65.29% | -26.68% | -11.11% | -8.71% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $32.93M | -121.04% | -43.71% | -4.52% | 10.54% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | 0.00% | 0.00% | 0.00% | -322.60% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | 0.00% | 0.00% | 0.00% | -479.12% |
Operating Margin
-149.8%
Net Profit Margin
426.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -315.04% |
| 2026-03-31 | -239.85% |
| 2025-12-31 | 2164.20% |
| 2025-09-30 | -116.40% |
| 2025-06-30 | -153.44% |
| 2025-03-31 | -65.22% |
| 2024-12-31 | -165.71% |
| 2024-09-30 | 21.72% |
| 2024-06-30 | -447.94% |
| 2024-03-31 | -268.81% |
| 2023-12-31 | -158.54% |
| 2023-09-30 | -159.08% |
| 2023-06-30 | -167.23% |
| 2023-03-31 | -124.75% |
| 2022-12-31 | -42.95% |
| 2022-09-30 | -169.43% |
| 2022-06-30 | -74.36% |
| 2022-03-31 | -70.89% |
| 2021-12-31 | -83.45% |
| 2021-09-30 | -72.41% |
